Paper · 37559592

Variant allele frequency changes in TP53 predict pembrolizumab response in patients with metastatic urothelial carcinoma.

Hamada K and 9 others. Oncol Lett, 2023. Cited by 5 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Variant allele frequency changes in TP53 predict pembrolizumab response in patients with metastatic urothelial carcinoma. Papers, record 37559592. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37559592

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Variant allele frequency changes in TP53 predict pembrolizumab response in patients with metastatic urothelial carcinoma.; PubMed
Journal: Oncol Lett; PubMed
Year: 2023; PubMed
Publication types: Journal Article; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/37559592/; PubMed
DOI: https://doi.org/10.3892/ol.2023.13975; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC10407860/; PubMed
The journal: https://conductscience.org/library/journal-index/101531236; PubMed
Citations, by iCite: 5; iCite
Relative citation ratio, by iCite: 0.43; iCite
Revised in PubMed: 2023-08-11; PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Hamada K	Kazuki
2	Nagumo Y	Yoshiyuki
3	Kandori S	Shuya
4	Tanuma K	Kozaburo
5	Shiga M	Masanobu
6	Hoshi A	Akio
7	Negoro H	Hiromitsu
8	Kojima T	Takahiro
9	Mathis BJ	Bryan J
10	Nishiyama H	Hiroyuki

Source PubMed

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References27

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	35,562,252	Circulating Tumour DNA Is a Strong Predictor of Outcomes in Patients Treated with Systemic Therapy for Urothelial Carcinoma.	Eur Urol Focus	2022	https://conductscience.org/library/papers/35562252	PubMed
2	19,097,774	New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).	Eur J Cancer	2009	https://conductscience.org/library/papers/19097774	PubMed
3	28,196,593	Liquid Biopsies, What We Do Not Know (Yet).	Cancer Cell	2017	https://conductscience.org/library/papers/28196593	PubMed
4	33,125,859	The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker.	Cancer Cell	2021	https://conductscience.org/library/papers/33125859	PubMed
5	31,285,372	Use of Circulating Tumor DNA for Cancer Immunotherapy.	Clin Cancer Res	2019	https://conductscience.org/library/papers/31285372	PubMed
6	27,718,847	Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.	N Engl J Med	2016	https://conductscience.org/library/papers/27718847	PubMed
7	27,939,400	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.	Lancet	2017	https://conductscience.org/library/papers/27939400	PubMed
8	28,212,060	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.	N Engl J Med	2017	https://conductscience.org/library/papers/28212060	PubMed
9	32,407,439	Outcomes Following Immune Checkpoint Inhibitor Treatment of Patients With Microsatellite Instability-High Cancers: A Systematic Review and Meta-analysis.	JAMA Oncol	2020	https://conductscience.org/library/papers/32407439	PubMed
10	30,643,254	Tumor mutational load predicts survival after immunotherapy across multiple cancer types.	Nat Genet	2019	https://conductscience.org/library/papers/30643254	PubMed

1 to 10 of 27

See all 27 references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMID	Title	Journal	Year	In Papers	Source
42,870,280	Liquid biopsy in bladder cancer: towards precision oncology.	J Transl Med	2026	https://conductscience.org/library/papers/42870280	PubMed
42,038,393	Circulating tumor DNA as a prognostic and monitoring biomarker in urothelial cancers.	Front Oncol	2026	https://conductscience.org/library/papers/42038393	PubMed
40,234,713	Circulating tumour DNA and circulating tumour cells in bladder cancer - from discovery to clinical implementation.	Nat Rev Urol	2025	https://conductscience.org/library/papers/40234713	PubMed

Genes9

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes	Source
CD274	29,126	PubTator's text mining	https://conductscience.org/library/genes/29126	NCBI Gene
EGFR	1,956	PubTator's text mining	https://conductscience.org/library/genes/1956	NCBI Gene
ERBB2	2,064	PubTator's text mining	https://conductscience.org/library/genes/2064	NCBI Gene
GNA11	2,767	PubTator's text mining	https://conductscience.org/library/genes/2767	NCBI Gene
KDR	3,791	PubTator's text mining	https://conductscience.org/library/genes/3791	NCBI Gene
PTEN	5,728	PubTator's text mining	https://conductscience.org/library/genes/5728	NCBI Gene
RAF1	5,894	PubTator's text mining	https://conductscience.org/library/genes/5894	NCBI Gene
RB1	5,925	PubTator's text mining	https://conductscience.org/library/genes/5925	NCBI Gene
TP53	7,157	PubTator's text mining	https://conductscience.org/library/genes/7157	NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37559592

GET https://conductscience.org/api/papers/v1/37559592/references?page=2

API reference For AI assistants